Verified Nov 2026
Batteries & E-Mobility
·

San Diego, California
·
Since 2014
ImmunityBio, Inc. is a clinical-stage biotechnology company founded in 2014 and headquartered in San Diego, California. With 500–1,000 employees and an estimated revenue band of $100–250 million, the company develops next-generation immunotherapies targeting cancer and infectious diseases. Its lead product, ANKTIVA (N-803), an IL-15 superagonist, received FDA approval in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer and has expanded into lung cancer indications.
ImmunityBio, Inc. at a glance
Revenue
$100-250M
Est. band
Employees
500-1,000
Founded
2014
Headquarters
San Diego, California
Industries
Automotive
Electric Vehicles
Medical
Overview
ImmunityBio, Inc. is a clinical-stage biotechnology company founded in 2014 and headquartered in San Diego, California. With 500–1,000 employees and an estimated revenue band of $100–250 million, the company develops next-generation immunotherapies targeting cancer and infectious diseases. Its lead product, ANKTIVA (N-803), an IL-15 superagonist, received FDA approval in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer and has expanded into lung cancer indications.
At a glance
Attribute | Detail |
|---|---|
Founded | 2014 |
Headquarters | San Diego, California |
Employees | 500-1,000 |
Revenue | $100-250M (estimated) |
Primary capability | Batteries & E-Mobility |
What ImmunityBio, Inc. makes
The company's pipeline includes immunotherapy candidates targeting advanced solid tumors, colorectal cancer, glioblastoma, HIV, and HPV, with clinical trials conducted in collaboration with institutions such as the National Cancer Institute.
Latest developments
2026-11-09 — ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million - ImmunityBio, Inc. (immunitybio.com)
2026-05-16 — ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States - ImmunityBio, Inc. (immunitybio.com)
2026-04-26 — ImmunityBio Secures Revised Dunkirk Manufacturing Deal with Stricter Terms and $40M Investment Commitment - MedPath Trial (medpath.com)
2026-03-31 — ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline - ImmunityBio, Inc. (immunitybio.com)
2026-02-23 — ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally - ImmunityBio, Inc. (immunitybio.com)
2026-02-19 — ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch - ImmunityBio (immunitybio.com)
Facilities
ImmunityBio, Inc. is headquartered in San Diego, California. Public sources also reference these locations:
Dunkirk, New York — medpath.com
Company details
ImmunityBio reported net product revenue of $48.7 million in Q3 2026, representing 53 percent year-over-year growth, and operates as a subsidiary of NantWorks LLC. ImmunityBio, Inc. was founded in 2014, has an estimated 500-1,000 employees, and is headquartered in San Diego, California.
Frequently asked questions
What does ImmunityBio, Inc. make?
ImmunityBio, Inc. is a clinical-stage biotechnology company founded in 2014 and headquartered in San Diego, California. With 500–1,000 employees and an estimated revenue band of $100–250 million, the company develops next-generation immunotherapies targeting cancer and infectious diseases. Its lead product, ANKTIVA (N-803), an IL-15 superagonist, received FDA approval in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer and has expanded into lung cancer indications.
Where is ImmunityBio, Inc. headquartered?
ImmunityBio, Inc. is headquartered in San Diego, California (3530 John Hopkins Ct, San Diego, California, 92121-1121).
When was ImmunityBio, Inc. founded?
ImmunityBio, Inc. was founded in 2014.
How big is ImmunityBio, Inc.?
ImmunityBio, Inc. has an estimated 500-1,000 employees, with revenue in the $100-250M range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
